Abstract | OBJECTIVE: Because of the limited efficacy of available agents and to limit toxicity, there is considerable interest in combination pharmacotherapy for osteoporosis. METHODS: A search was performed for randomized controlled trials in MEDLINE (1966-present) using the keywords osteoporosis treatment and combination. RESULTS: CONCLUSIONS: The few trials including Food and Drug Administration (FDA)-approved medications suggest that 10 mg/day alendronate with estrogen (equivalent of 0.625 mg CEE daily) can increase BMD moreso than each medication given singly in postmenopausal osteoporotic women. Estrogen dose and type must be controlled in future trials. Long-term safety data are lacking. The utility of these combinations rests on whether bone density changes will translate into decreased fracture rates.
|
Authors | Carolyn Crandall |
Journal | Journal of women's health & gender-based medicine
(J Womens Health Gend Based Med)
Vol. 11
Issue 3
Pg. 211-24
(Apr 2002)
ISSN: 1524-6094 [Print] United States |
PMID | 11988132
(Publication Type: Comparative Study, Journal Article, Review)
|
Chemical References |
- Estrogens, Conjugated (USP)
- Alendronate
|
Topics |
- Alendronate
(administration & dosage, therapeutic use)
- Bone Density
- Clinical Trials as Topic
- Drug Therapy, Combination
- Estrogens, Conjugated (USP)
(administration & dosage, therapeutic use)
- Female
- Humans
- Osteoporosis
(drug therapy)
- Osteoporosis, Postmenopausal
(drug therapy)
- Randomized Controlled Trials as Topic
|